Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005:103:368-411.

Quality of life in patients with Graves ophthalmopathy

R Patrick Yeatts  1
Affiliations

Quality of life in patients with Graves ophthalmopathy

R Patrick Yeatts. Trans Am Ophthalmol Soc. 2005.

Abstract

Purpose: To assess the quality of life in patients with Graves ophthalmopathy by means of a prospective questionnaire with validation.

Methods: A questionnaire containing 105 items was sent to 325 patients seen in our university-based oculoplastic clinic. Two hundred three questionnaires were returned and were suitable for analysis. Fifty-three consecutive patients with Graves disease who presented to the clinic for examination also completed the questionnaire. The questionnaire was validated by administering it to 33 healthy subjects who had no history of Graves disease or thyroid disorder. The results were compared with those of normal subjects and with national norms for visually impaired populations. The relationship of individual questionnaire items to measures of clinical severity was subsequently assessed.

Results: Patients with Graves ophthalmopathy report greater impairment in both physical (44.4 versus 51.9; P < .001) and mental (43.8 versus 51.8; P < .001) health; poorer self- image (P < .001); and significantly more disturbance in their sleep, social function, and work function (P < .001) than controls. Afflicted patients also experience significantly more diplopia, blurred vision, and dry eye symptoms than controls (P < .001). Individual questionnaire items were found to correlate with clinical disease severity scores and were used to establish a Graves ophthalmopathy quality-of-life questionnaire with disease severity validation.

Conclusions: Patients with Graves disease are significantly impaired in their social and vocational function because of the ophthalmic manifestations of the disease. A short questionnaire that correlates with clinical measures of disease severity may be a useful measure of quality of life in this disease.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Scatter plot of myopathy severity scores versus quality of life in Graves study group. Pearson correlation = −.23; regression slope significant at α = .001, P =.0007.
FIGURE 2
FIGURE 2
Scatter plot of neuropathy severity score versus quality of life in Graves study group. Pearson correlation = −39; regression slope significant at α = .001, P < .0001.
FIGURE 3
FIGURE 3
Scatter plot of cosmesis severity score versus quality of life in Graves study group. Pearson correlation = −.24; regression slope significant at α = .001, P = .0003.
FIGURE 4
FIGURE 4
Scatter plot of keratopathy severity score versus quality of life in Graves study group. Pearson correlation = −.14; regression slope significant at α = .05, P = .0407.
APPENDIX 1 FIGURE 1
APPENDIX 1 FIGURE 1
Page 1, Graves Quality-of-Life Questionnaire.
APPENDIX 1 FIGURE 2
APPENDIX 1 FIGURE 2
Page 2, Graves Quality-of-Life Questionnaire.
APPENDIX 1 FIGURE 3
APPENDIX 1 FIGURE 3
Page 3, Graves Quality-of-Life Questionnaire.
APPENDIX 1 FIGURE 4
APPENDIX 1 FIGURE 4
Page 4, Graves Quality-of-Life Questionnaire.
APPENDIX 1 FIGURE 5
APPENDIX 1 FIGURE 5
Page 5, Graves Quality-of-Life Questionnaire.
APPENDIX 1 FIGURE 6
APPENDIX 1 FIGURE 6
Page 6, Graves Quality-of-Life Questionnaire.
APPENDIX 1 FIGURE 7
APPENDIX 1 FIGURE 7
Page 7, Graves Quality-of-Life Questionnaire.
APPENDIX 1 FIGURE 8
APPENDIX 1 FIGURE 8
Page 8, Graves Quality-of-Life Questionnaire.
APPENDIX 1 FIGURE 9
APPENDIX 1 FIGURE 9
Page 9, Graves Quality-of-Life Questionnaire.
APPENDIX 1 FIGURE 10
APPENDIX 1 FIGURE 10
Page 10, Graves Quality-of-Life Questionnaire.
APPENDIX 1 FIGURE 11
APPENDIX 1 FIGURE 11
Page 11, Graves Quality-of-Life Questionnaire.
APPENDIX 1 FIGURE 12
APPENDIX 1 FIGURE 12
Page 12, Graves Quality-of-Life Questionnaire.
APPENDIX 1 FIGURE 13
APPENDIX 1 FIGURE 13
Page 13, Graves Quality-of-Life Questionnaire.
See this image and copyright information in PMC

References

    1. Bartley GB, Fatourechi V, Kadramas EF, et al. Clinical features of Graves’ ophthalmopathy in an incident cohort. Am J Ophthalmol. 1996;121:284–290. - PubMed
    1. Bartley GB, Fatourechi V, Kadrmas EF, et al. Long-term follow-up of Graves ophthalmopathy in an incident cohort. Ophthalmology. 1996;106:958–962. - PubMed
    1. Burch HB, Wartofsky L. Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev. 1993;14:747–793. - PubMed
    1. Weetman AP. Thyroid-associated eye disease: pathophysiology. Lancet. 1991;338:25–28. - PubMed
    1. Hales IB, Rundle FF. Ocular changes in Graves’ disease: a long-term follow-up study. Q J Med. 1960;29:113–126. - PubMed

Publication types